-
Reports: Court upholds Abilify patent
NEW YORK — A generic version of a schizophrenia drug made by Otsuka Holdings and Bristol-Myers Squibb can't be launched until April 2015, according to published reports.
Bloomberg reported that the U.S. Court of Appeals for the Federal Circuit upheld the validity of patents covering Abilify (aripiprazole) in the two companies' lawsuit against Teva Pharmaceutical Industries and Apotex.
According to IMS Health, Abilify was the fourth top-selling drug in the United States in 2011, with sales of $5.2 billion. -
NCPA seeks legislative relief to the business challenges faced by community pharmacy
WASHINGTON — Community pharmacy operators are the "canary in the coal mine" when it comes to federal or state prescription programs, said Douglas Hoey, CEO for the National Community Pharmacists Association, during a press conference held Tuesday afternoon.